Noxopharm at-a-glance
• Australian biotechnology company. Offices Sydney, New York, Hong Kong
• Playing to our strength.... isoflavonoid drug platform
• Aiming to bring Veyonda® to market as a first-in-class companion drug to radiotherapy
• Mixture of out-licensing and in-house sales/marketing
• Cash: AUD$9.6 million (Sept 30) (+ R&D rebate pending)
To view Presentation please download PDF attached:
Download this document
